Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
November 14, 2018
DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results
VANCOUVER, British Columbia and MENLO PARK, Calif., Nov. 14, 2018 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the ...
November 14, 2018
Athenex, Inc. Announces Third Quarter 2018 Financial Results and Provides Corporate Update
BUFFALO, N.Y., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies ...
November 14, 2018
ArQule to Present at the 30th Annual Piper Jaffray Healthcare Conference on November 28, 2018
BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President, Head of Strategy, Finance, and Communication ...
November 14, 2018
RedHill Biopharma Announces Presentation on YELIVA® (opaganib) for Multiple Myeloma at EORTC-NCI-AACR Symposium
TEL-AVIV, Israel and RALEIGH, N.C., Nov. 14, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty ...
November 14, 2018
Circulating Tumor Cells Detected From Angiosarcoma Cancer Patients With Use Of ApoStream® Technology In A First-of-its-kind Study
HOUSTON, Nov. 14, 2018 /PRNewswire/ -- Precision for Medicine and TRACON Pharmaceuticals (TCON) announced today the presentation of biomarker results from the TAPPAS phase 3 clinical ...
November 14, 2018
Prometic Closes its Extension of Debt Maturities to 2024
LAVAL, QC , Nov. 14, 2018 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF)("Prometic" or the "Corporation") announced today that it has closed the transaction previously disclosed ...
November 14, 2018
CorMedix Inc. Reports Third Quarter Financial Results and Provides Business Update
BERKELEY HEIGHTS, NJ / ACCESSWIRE / November 14, 2018 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products ...
November 14, 2018
Veloxis Pharmaceuticals Announces Financial Results for the First Nine Months of 2018 Highlights
COPENHAGEN, Denmark, Nov. 14, 2018 /PRNewswire/ -- Highlights Product revenue for first nine months of 2018 was USD 27.8 million, an increase of 101% compared ...
November 14, 2018
Neovasc Announces Third Quarter 2018 Financial Results
VANCOUVER , Nov. 14, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN TSX: NVCN), a leader in the development of minimally invasive ...
November 14, 2018
AIT Therapeutics Reports Financial Results for Fiscal Second Quarter 2019
GARDEN CITY, N.Y. and REHOVOT, Israel, Nov. 14, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on ...
November 14, 2018
CohBar Reports Third Quarter 2018 Financial Results and Provides Business Update
MENLO PARK, Calif., Nov. 14, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related ...
November 14, 2018
Zosano Pharma Reports Third Quarter 2018 Financial Results and Operational Update
FREMONT,Calif., Nov. 14, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company, today announced financial results for the ...
November 14, 2018
Avenue Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
NEW YORK, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of intravenous ...
November 14, 2018
EDAP TMS SA : EDAP Reports 2018 Third Quarter Results
LYON, France, November 14, 2018 -- EDAP TMS SA (EDAP) ("the Company"), the global leader in therapeutic ultrasound, announced today financial results for the third ...
November 5, 2018
Genkyotex Meets Both Primary and Secondary Interim Efficacy Endpoints in Phase 2 Trial of GKT831 in Primary Biliary Cholangitis
Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR00011790542 – GKTX) announced today that its lead product candidate GKT831, a NOX1/4 inhibitor, met both the primary ...
November 5, 2018
Onxeo Announces Positive Interim Results from Phase 1 Study of AsiDNATM, a First-In-Class DNA Damage Response Inhibitor
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology targeting tumor DNA Damage Response ...
November 5, 2018
Check-Cap Reports Third Quarter 2018 Financial Results
ISFIYA, Israel, Nov. 5, 2018 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (CHEK) (NASDAQ:CHEKW), (NASDAQ:CHEKZ), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, ...
November 5, 2018
Orchard Therapeutics Announces Closing of $225 Million Initial Public Offering, Including the Partial Exercise of Underwriters’ Option
BOSTON and LONDON, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics plc (ORTX), a biopharmaceutical company dedicated to transforming the lives of patients with serious ...
November 5, 2018
UroGen Pharma to Report Third Quarter 2018 Financial Results on Monday, November 12, 2018
RA’ANANA, Israel & NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (URGN) today announced that it will report third quarter 2018 financial results on Monday, November 12, 2018, ...
November 5, 2018
Krystal Biotech Reports Third Quarter 2018 Financial Results and Provides Corporate Update
PITTSBURGH, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech (KRYS), a gene therapy company advancing “off-the-shelf” topical and intra-dermal treatments for skin diseases, today reported ...
Page 27 of 138